New injection schedule may boost vision in diabetic eye disease
NCT ID NCT04116398
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a new treatment plan for diabetic macular edema, a condition that causes vision loss. Instead of waiting for severe swelling, patients receive two dexamethasone implants 12 weeks apart, then additional injections only as needed. The goal is to improve vision while keeping the number of injections low. The trial includes 53 adults with significant macular thickening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dexamethasone implant (Ozurdex)
What this could lead to
If successful, this could offer a more effective treatment schedule for diabetic macular edema, potentially improving vision while reducing the number of injections needed.
What could go wrong
This is a small, early-phase study with only 53 participants, so results may not apply to everyone. The treatment involves eye injections, which carry risks like infection or increased eye pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM - Hôpital Nord
Marseille, 13015, France
-
APHP - Hôpital Avicenne
Bobigny, 93000, France
-
APHP - Hôpital Lariboisière
Paris, 75010, France
-
CHRU Lille - Hôpital Huriez
Lille, 59037, France
-
CHU Bordeaux - Hôpital Pellegrin
Bordeaux, 33000, France
-
CHU Dijon
Dijon, 21079, France
-
CHU Toulouse - Hôpital Pierre Paul Riquet
Toulouse, 31059, France
-
CHU de Poitiers - La miletrie
Poitiers, 86000, France
-
Centre Hospitalier National d'Ophtalmologie des XV XX
Paris, 75012, France
-
Centre Monticelli Paradis d'ophtalmologie
Marseille, 13008, France
-
Centre Rétine Gallien
Bordeaux, France
-
Clinique Juge
Marseille, France
-
Clinique Mathilde
Rouen, France
-
Hospices Civils de Lyon - Hopital de la Croix Rousse
Lyon, 69004, France
-
Hôpital Edouard Herriot
Lyon, 69003, France
-
Hôpital Intercommunal de Créteil
Créteil, 94010, France